Total Valuation
Supernus Pharmaceuticals has a market cap or net worth of $2.59B. The enterprise value is $2.37K.
Market Cap$2.59B
Enterprise Value$2.37K
Share Statistics
Supernus Pharmaceuticals has 58,039,722 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,039,722
Owned by Insiders4.30%
Owned by Institutions3.71%
Financial Efficiency
Supernus Pharmaceuticals’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -2.58%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.03
Return on Invested Capital (ROIC)-2.58%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee924.10K
Profits Per Employee-49.55K
Employee Count778
Asset Turnover0.49
Inventory Turnover0.91
Valuation Ratios
The current PE Ratio of Supernus Pharmaceuticals is ―. Supernus Pharmaceuticals’s PEG ratio is 0.48.
PE Ratio―
PS Ratio3.90
PB Ratio2.64
Price to Fair Value2.64
Price to FCF61.00
Price to Operating Cash Flow136.37
PEG Ratio0.48
Income Statement
In the last 12 months, Supernus Pharmaceuticals had revenue of 718.95M and earned -38.55M in profits. Earnings per share was -0.68.
Revenue718.95M
Gross Profit644.39M
Operating Income-36.86M
Pretax Income-49.03M
Net Income-38.55M
EBITDA42.53M
Earnings Per Share (EPS)-0.68
Cash Flow
In the last 12 months, operating cash flow was 19.91M and capital expenditures -1.12M, giving a free cash flow of 18.79M billion.
Operating Cash Flow19.91M
Free Cash Flow18.79M
Free Cash Flow per Share0.32
Dividends & Yields
Supernus Pharmaceuticals pays an annual dividend of $0.285, resulting in a dividend yield of ―
Dividend Per Share$0.285
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change13.14%
50-Day Moving Average46.34
200-Day Moving Average48.97
Relative Strength Index (RSI)52.78
Average Volume (3m)15.00
Important Dates
Supernus Pharmaceuticals upcoming earnings date is Nov 10, 2026, After Close (Confirmed).
Last Earnings DateAug 3, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Supernus Pharmaceuticals as a current ratio of 1.90, with Debt / Equity ratio of 3.90%
Current Ratio1.90
Quick Ratio1.66
Debt to Market Cap0.00
Net Debt to EBITDA-2.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Supernus Pharmaceuticals has paid -10.48M in taxes.
Income Tax-10.48M
Effective Tax Rate0.21
Enterprise Valuation
Supernus Pharmaceuticals EV to EBITDA ratio is 63.91, with an EV/FCF ratio of 59.10.
EV to Sales3.78
EV to EBITDA63.91
EV to Free Cash Flow59.10
EV to Operating Cash Flow57.43
Balance Sheet
Supernus Pharmaceuticals has $372.07M in cash and marketable securities with $40.17M in debt, giving a net cash position of $331.90M billion.
Cash & Marketable Securities$372.07M
Total Debt$40.17M
Net Cash$331.90M
Net Cash Per Share$5.72
Tangible Book Value Per Share$6.51
Margins
Gross margin is 88.07%, with operating margin of -5.13%, and net profit margin of -5.36%.
Gross Margin88.07%
Operating Margin-5.13%
Pretax Margin-6.82%
Net Profit Margin-5.36%
EBITDA Margin5.92%
EBIT Margin-6.82%
Analyst Forecast
The average price target for Supernus Pharmaceuticals is $65.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$65.20
Price Target Upside36.74% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast16.29%
EPS Growth Forecast-145.12%